HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Kazuhiro Nagahira Selected Research

3- (1- (4- phenoxyphenyl)- 3- (2- phenylethyl)- 1H- indol- 5- yl)propanoic acid

3/2016ASB14780, an Orally Active Inhibitor of Group IVA Phospholipase A2, Is a Pharmacotherapeutic Candidate for Nonalcoholic Fatty Liver Disease.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Kazuhiro Nagahira Research Topics

Disease

4Inflammation (Inflammations)
03/2016 - 12/2008
4Dermatitis
10/2011 - 04/2007
2Myasthenia Gravis
01/2018 - 01/2017
2Edema (Dropsy)
09/2014 - 06/2009
2Atopic Dermatitis (Atopic Eczema)
10/2011 - 12/2008
1Abdominal Aortic Aneurysm
08/2019
1Experimental Autoimmune Myasthenia Gravis (Autoimmune Experimental Myasthenia Gravis)
01/2018
1Muscle Weakness
01/2017
1Autoimmune Diseases (Autoimmune Disease)
01/2017
1Fatty Liver
03/2016
1Fibrosis (Cirrhosis)
03/2016
1Non-alcoholic Fatty Liver Disease
03/2016
1Asthma (Bronchial Asthma)
09/2014
1Hyperplasia
05/2010
1Psoriasis (Pustulosis Palmaris et Plantaris)
05/2010
1Hepatitis
10/2009
1Pruritus (Itching)
12/2008
1Babesiosis (Piroplasmosis)
09/2003

Drug/Important Bio-Agent (IBA)

4Chymases (Chymase)IBA
08/2019 - 04/2007
3Phosphoric Diester Hydrolases (Phosphodiesterases)IBA
05/2010 - 06/2009
2Nicotinic Receptors (Nicotinic Acetylcholine Receptor)IBA
01/2018 - 01/2017
26- (5- chloro- 2- methoxybenzyl)- 4- alarkylaminocarbonyl- 1,4- diazepane- 2,5- dioneIBA
10/2011 - 12/2008
21- cyclohexyl- N- (6- (4- hydroxy- 1- piperidinyl)- 3- pyridinyl)- 3- methyl- 1H- thieno(2,3- c)pyrazole- 5- carboxamideIBA
05/2010 - 06/2009
2Pharmaceutical PreparationsIBA
10/2009 - 09/2003
2Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA
10/2009 - 06/2009
1ApolipoproteinsIBA
08/2019
1Angiotensin IIIBA
08/2019
1Monoclonal AntibodiesIBA
01/2018
1AntibodiesIBA
01/2018
1AutoantibodiesIBA
01/2017
1Group IV Phospholipases A2IBA
03/2016
1SaltsIBA
03/2016
13- (1- (4- phenoxyphenyl)- 3- (2- phenylethyl)- 1H- indol- 5- yl)propanoic acidIBA
03/2016
1LipidsIBA
03/2016
1CholesterolIBA
03/2016
1PropaneIBA
03/2016
1PropionatesIBA
03/2016
1Carbon Tetrachloride (Tetrachloromethane)IBA
03/2016
1phorbolIBA
09/2014
1Acetates (Acetic Acid Esters)FDA Link
09/2014
1OvalbuminIBA
09/2014
1Picryl Chloride (Trinitrochlorobenzene)IBA
10/2011
1alpha-galactosylceramideIBA
10/2009
1Interleukin-4 (Interleukin 4)IBA
10/2009
1CytokinesIBA
10/2009
1Concanavalin AIBA
10/2009
11- cyclohexyl- N- (3- fluoro- 4- (4- methyl- 1- piperazinyl)phenyl)- 3- methyl- 1H- thieno(2,3- c)pyrazole- 5- carboxamideIBA
10/2009
1Phorbol EstersIBA
06/2009
1DinitrofluorobenzeneIBA
12/2008
1ImidocarbIBA
09/2003
1Interleukin-10 (Interleukin 10)IBA
09/2003

Therapy/Procedure

2Oral Administration
10/2011 - 04/2007